Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Olema Oncology
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
November 2, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 13, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
August 13, 2026
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
August 12, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
1
2
Next Page
→